NO133200B - - Google Patents
Download PDFInfo
- Publication number
- NO133200B NO133200B NO4276/68A NO427668A NO133200B NO 133200 B NO133200 B NO 133200B NO 4276/68 A NO4276/68 A NO 4276/68A NO 427668 A NO427668 A NO 427668A NO 133200 B NO133200 B NO 133200B
- Authority
- NO
- Norway
- Prior art keywords
- cis
- salts
- acid
- solution
- mol
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 claims description 27
- XWCIXXXLOAAWPU-IHWYPQMZSA-N [(z)-prop-1-enyl]phosphonic acid Chemical group C\C=C/P(O)(O)=O XWCIXXXLOAAWPU-IHWYPQMZSA-N 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 8
- 230000000844 anti-bacterial effect Effects 0.000 claims description 4
- 239000007858 starting material Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- -1 monoalkylamines Chemical class 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 239000003054 catalyst Substances 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 239000001257 hydrogen Substances 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 7
- 238000005984 hydrogenation reaction Methods 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- YYTYLIVWHBVGKW-UHFFFAOYSA-N 1-[butoxy(prop-1-ynyl)phosphoryl]oxybutane Chemical compound C(CCC)OP(OCCCC)(=O)C#CC YYTYLIVWHBVGKW-UHFFFAOYSA-N 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 244000052616 bacterial pathogen Species 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- JYDBWTLMEMXTBB-UHFFFAOYSA-N 1-[butoxy-[(Z)-prop-1-enyl]phosphoryl]oxybutane Chemical compound C(CCC)OP(OCCCC)(=O)C=C/C JYDBWTLMEMXTBB-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 3
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 3
- 229910000564 Raney nickel Inorganic materials 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 229940046892 lead acetate Drugs 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000003973 paint Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- XYPISWUKQGWYGX-UHFFFAOYSA-N 2,2,2-trifluoroethaneperoxoic acid Chemical compound OOC(=O)C(F)(F)F XYPISWUKQGWYGX-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- 239000007818 Grignard reagent Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- DXMAARCZJITWJZ-UHFFFAOYSA-L [Mg+2].[Br-].[Br-].CC#C Chemical compound [Mg+2].[Br-].[Br-].CC#C DXMAARCZJITWJZ-UHFFFAOYSA-L 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000006286 aqueous extract Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- CQPJLZWBXXBTJA-UHFFFAOYSA-N prop-1-ynylphosphonic acid Chemical class CC#CP(O)(O)=O CQPJLZWBXXBTJA-UHFFFAOYSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- ZJEHRMYJNACSLL-UHFFFAOYSA-N 1-[butoxy(chloro)phosphoryl]oxybutane Chemical compound CCCCOP(Cl)(=O)OCCCC ZJEHRMYJNACSLL-UHFFFAOYSA-N 0.000 description 1
- LDVWNVNTGFDILM-UHFFFAOYSA-N 1-di(propan-2-yloxy)phosphorylprop-1-yne Chemical compound CC#CP(=O)(OC(C)C)OC(C)C LDVWNVNTGFDILM-UHFFFAOYSA-N 0.000 description 1
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- GUFGWNUUDBGEGH-UHFFFAOYSA-N 2-[chloro(propan-2-yloxy)phosphoryl]oxypropane Chemical compound CC(C)OP(Cl)(=O)OC(C)C GUFGWNUUDBGEGH-UHFFFAOYSA-N 0.000 description 1
- 229940058020 2-amino-2-methyl-1-propanol Drugs 0.000 description 1
- GRWKNBPOGBTZMN-UHFFFAOYSA-N 2-benzyl-3-phenylpropane-1,2-diamine Chemical compound C=1C=CC=CC=1CC(N)(CN)CC1=CC=CC=C1 GRWKNBPOGBTZMN-UHFFFAOYSA-N 0.000 description 1
- GLVYLTSKTCWWJR-UHFFFAOYSA-N 2-carbonoperoxoylbenzoic acid Chemical compound OOC(=O)C1=CC=CC=C1C(O)=O GLVYLTSKTCWWJR-UHFFFAOYSA-N 0.000 description 1
- WGTASENVNYJZBK-UHFFFAOYSA-N 3,4,5-trimethoxyamphetamine Chemical compound COC1=CC(CC(C)N)=CC(OC)=C1OC WGTASENVNYJZBK-UHFFFAOYSA-N 0.000 description 1
- QWMFKVNJIYNWII-UHFFFAOYSA-N 5-bromo-2-(2,5-dimethylpyrrol-1-yl)pyridine Chemical compound CC1=CC=C(C)N1C1=CC=C(Br)C=N1 QWMFKVNJIYNWII-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- RHHUYYMDAHUVSI-UHFFFAOYSA-N C(C)(C)OP(OC(C)C)(=O)C=C/C Chemical compound C(C)(C)OP(OC(C)C)(=O)C=C/C RHHUYYMDAHUVSI-UHFFFAOYSA-N 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical class C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000588772 Morganella morganii Species 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- 241000607132 Salmonella enterica subsp. enterica serovar Gallinarum Species 0.000 description 1
- 241000607683 Salmonella enterica subsp. enterica serovar Pullorum Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- YYYYLWPWZWOIMP-UHFFFAOYSA-L [Na+].[Na+].OP(O)=O.[O-]P([O-])=O Chemical compound [Na+].[Na+].OP(O)=O.[O-]P([O-])=O YYYYLWPWZWOIMP-UHFFFAOYSA-L 0.000 description 1
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- IMUDHTPIFIBORV-UHFFFAOYSA-N aminoethylpiperazine Chemical compound NCCN1CCNCC1 IMUDHTPIFIBORV-UHFFFAOYSA-N 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- WGQKYBSKWIADBV-UHFFFAOYSA-O benzylaminium Chemical compound [NH3+]CC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-O 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- RRKTZKIUPZVBMF-IBTVXLQLSA-N brucine Chemical compound O([C@@H]1[C@H]([C@H]2C3)[C@@H]4N(C(C1)=O)C=1C=C(C(=CC=11)OC)OC)CC=C2CN2[C@@H]3[C@]41CC2 RRKTZKIUPZVBMF-IBTVXLQLSA-N 0.000 description 1
- RRKTZKIUPZVBMF-UHFFFAOYSA-N brucine Natural products C1=2C=C(OC)C(OC)=CC=2N(C(C2)=O)C3C(C4C5)C2OCC=C4CN2C5C31CC2 RRKTZKIUPZVBMF-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- ITVPBBDAZKBMRP-UHFFFAOYSA-N chloro-dioxido-oxo-$l^{5}-phosphane;hydron Chemical compound OP(O)(Cl)=O ITVPBBDAZKBMRP-UHFFFAOYSA-N 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- 125000005265 dialkylamine group Chemical class 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000006735 epoxidation reaction Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 229940031098 ethanolamine Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical class C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 1
- 238000001030 gas--liquid chromatography Methods 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 150000003009 phosphonic acids Chemical class 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- NSETWVJZUWGCKE-UHFFFAOYSA-N propylphosphonic acid Chemical compound CCCP(O)(O)=O NSETWVJZUWGCKE-UHFFFAOYSA-N 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 229940007042 proteus vulgaris Drugs 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 125000005270 trialkylamine group Chemical class 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65502—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a three-membered ring
- C07F9/65505—Phosphonic acids containing oxirane groups; esters thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/14—Esters of phosphoric acids containing P(=O)-halide groups
- C07F9/1403—Esters of phosphoric acids containing P(=O)-halide groups containing the structure Hal-P(=O)-O-unsaturated acyclic group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
- C07F9/657181—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
Description
Foreliggende oppfinnelse angår en ny forbindelse, cis-propenylfosfonsyre og salter derav, for anvendelse som utgangs - materiale ved fremstilling av (cis-1,2-epoxypropyl)-fosfonsyre med antibakteriell virkning. The present invention relates to a new compound, cis-propenylphosphonic acid and salts thereof, for use as starting material in the production of (cis-1,2-epoxypropyl)-phosphonic acid with antibacterial action.
(-) (cis-1,2-epoxypropyl)-fosfonsyre og dens salter har en (-) (cis-1,2-epoxypropyl)-phosphonic acid and its salts have a
høy grad av antibakteriell aktivitet mot et stort antall patogene bakterier. ( t) (cis-1,2-epoxypropyl)-fosfonsyren og dens salter har også betraktelig antibakteriell aktivitet som på vektbasis er omtrent det halve av den for (-)-isomeren. Disse forbindelser er aktive til å inhibere veksten av såvel grampositive som gram-negativé patogene bakterier. De er aktive mot patogene bakterier av arter av Bacillus, Escherichia, Staphylococci, Salmonella og Proteus, og antibiotikumresistente varianter derav. Eksempler på slike patogene bakterier er Bacillus subtilis, Escherichia coli, Salmonella schottmuelleri , Salmonella gallinarum, Salmonella pullorum, Proteus vulgaris, Proteus mirabilis, Proteus morganii, Staphylococcus aureus og Staphylococcus pyogenes. (-) og (t) (cis-1,2-epoxypropyl)-fosfonsyren og salter derav kan således anvendes som antiseptiske midler for å fjerne påvirkelige organismer fra farmasøytisk, dentalt og medisinsk utstyr og andre områder som er utsatt for infeksjon av slike organismer, og å inhibere skadelig bakterievekst i industrielle malinger. Likeledes kan de anvendes for å skille visse mikroorganismer fra blandinger av mikroorganismer. De er nyttige ved behandling av lidelser bevirket av bakterielle infeksjoner i mennesker og dyr, og er særlig verdifulle i denne henseende da de er virksomme mot mange varianter av patogene bakterier som er resistente mot tidligere tilgjengelige anti-biot ika. high degree of antibacterial activity against a large number of pathogenic bacteria. The ( t ) (cis-1,2-epoxypropyl)-phosphonic acid and its salts also have considerable antibacterial activity which, on a weight basis, is about half that of the (-)-isomer. These compounds are active in inhibiting the growth of both gram-positive and gram-negative pathogenic bacteria. They are active against pathogenic bacteria of species of Bacillus, Escherichia, Staphylococci, Salmonella and Proteus, and antibiotic-resistant variants thereof. Examples of such pathogenic bacteria are Bacillus subtilis, Escherichia coli, Salmonella schottmuelleri, Salmonella gallinarum, Salmonella pullorum, Proteus vulgaris, Proteus mirabilis, Proteus morganii, Staphylococcus aureus and Staphylococcus pyogenes. (-) and (t) (cis-1,2-epoxypropyl)-phosphonic acid and salts thereof can thus be used as antiseptics to remove susceptible organisms from pharmaceutical, dental and medical equipment and other areas that are exposed to infection by such organisms , and to inhibit harmful bacterial growth in industrial paints. Likewise, they can be used to separate certain microorganisms from mixtures of microorganisms. They are useful in the treatment of disorders caused by bacterial infections in humans and animals, and are particularly valuable in this respect as they are effective against many varieties of pathogenic bacteria that are resistant to previously available anti-biotics.
Saltene av (-) og (-) (cis-1,2-epoxypropyl)-fosfonsyren er nyttige som preserveringsmidler ved industrielle anvendelser da de effektivt inhiberer uønsket bakterievekst i bakvann i papirfab- The salts of (-) and (-) (cis-1,2-epoxypropyl)-phosphonic acid are useful as preservatives in industrial applications as they effectively inhibit unwanted bacterial growth in waste water in papermaking
rikker og i malinger, f.eks. i polyvinylacetatlatexmaling. riches and in paints, e.g. in polyvinyl acetate latex paint.
Når (-) og (t) (cis-1,2-epoxypropyl)-fosfonsyren og dens salter anvendes for å bekjempe bakterier i mennesker og i lavere dyr, kan de administreres oralt i en doseform som kapsler eller tabletter, eller i væskeoppløsning eller suspensjon. Disse formu-leringer kan fremstilles under anvendelse av fortynningsmidler, granuleringsmidler , preserveringsmidler, bindemidler, smaksstoffer og belegningsmidler som er kjent i faget. (-) (cis-1,2-epoxypropyl)-fosfonsyren som omtales her, dreier planpolarisert lys i retning mot urviseren (til venstre sett fra iakttageren) når dreiningen av dens dinatriumsalt måles i vann (5% konsentrasjon) ved k05 nm. When (-) and (t) (cis-1,2-epoxypropyl)-phosphonic acid and its salts are used to combat bacteria in humans and in lower animals, they can be administered orally in a dosage form such as capsules or tablets, or in liquid solution or suspension. These formulations can be prepared using diluents, granulating agents, preservatives, binding agents, flavoring agents and coating agents known in the art. The (-) (cis-1,2-epoxypropyl)-phosphonic acid discussed here rotates plane-polarized light in a counter-clockwise direction (to the left as seen from the observer) when the rotation of its disodium salt is measured in water (5% concentration) at k05 nm.
Betegnelsen cis anvendt for å beskrive 1,2-epoxypropylfosfon-syreforbindelsene, betegner at hvert av hydrogenatomene bundet til carbonatomene 1 og 2 i propylfosfonsyren er på samme side av oxyd-ringen. Uttrykket "cis" er klart ved betegnelsen av cis-propenyl-fosfonsyreforbindelsene ifølge oppfinnelsen. The designation cis used to describe the 1,2-epoxypropylphosphonic acid compounds denotes that each of the hydrogen atoms bound to carbon atoms 1 and 2 in the propylphosphonic acid is on the same side of the oxide ring. The expression "cis" is clear in the designation of the cis-propenyl-phosphonic acid compounds according to the invention.
Et mål ved foreliggende oppfinnelse er å fremskaffe nye ut-gangsmaterialer som er nyttige ved syntetisering av ( + ) (cis-1,2-epoxypropyl)-fosfonsyre og (-)-enantiomeren derav. An aim of the present invention is to provide new starting materials which are useful in synthesizing (+) (cis-1,2-epoxypropyl)-phosphonic acid and the (-)-enantiomer thereof.
Cis-propenylfosfonsyren ifølge oppfinnelsen har formelen: The cis-propenylphosphonic acid according to the invention has the formula:
og oppfinnelsen omfatter også de organiske og uorganiske salter av denne forbindelse. and the invention also includes the organic and inorganic salts of this compound.
Strukturformelen for den nye forbindelse ifølge oppfinnelsen er for bekvemhets skyld vist som planformler ovenfor fordi konfigurasjonen er tilstrekkelig definert ved navnet cis-propenylfosfonsyre. For fullstendighets skyld kan imidlertid romkonfigura-sjonen angies strukturelt som følger: The structural formula for the new compound according to the invention is for convenience shown as planar formulas above because the configuration is sufficiently defined by the name cis-propenylphosphonic acid. However, for the sake of completeness, the room configuration can be stated structurally as follows:
Denne romkonfigurasjon er et kritisk, trekk ved foreliggende oppfinnelse fordi tidligere beskrevne propenylfosfonsyreforbindelsér har trans-konfigurasjonen, eller er blandinger av cis- og trans-isomerer, mens foreliggende oppfinnelse gir forbindelser i cis-form praktisk talt fri for trans-formen. This space configuration is a critical feature of the present invention because previously described propenylphosphonic acid compounds have the trans configuration, or are mixtures of cis and trans isomers, while the present invention provides compounds in the cis form practically free of the trans form.
Saltene av forbindelsen av formel I utgjør en særlig fore-trukken utførelsesform av oppfinnelsen fordi de er meget nyttige ved fremstilling av (t) (cis-1,2-epoxypropyl)-fosfonsyreforbindelser. The salts of the compound of formula I constitute a particularly preferred embodiment of the invention because they are very useful in the preparation of (t) (cis-1,2-epoxypropyl)-phosphonic acid compounds.
De frie fosfonsyreforbindelser vil danne både organiske og uorganiske salter, og begge er innbefattet i oppfinnelsen. Eksempler på slike salter er uorganiske metallsalter, som natrium-, aluminium-, kalium-, ammonium-, calcium-, magnesium-, sølv- og jernsaltene. Organiske salter som kan nevnes som representative, innbefatter saltene av primære, sekundære eller tertiære aminer som monoalkylaminer, dialkylaminer, trialkylaminer og nitrogen-holdige heterocycliske aminer. Representative eksempler er salter med aminer som a-fenethylamin, diethylamin, diethylentriamin, kinin, brucin, lysin, protamin, arginin, procain, ethanolamin, morfin, benzylamin, ethylendiamin, N,N<*->dibenzylethylendiamin, diethanolamin, piperazin, N-aminoethylpiperazin, dimethylamino-ethanol , 2-amino-2-methyl-1-propanol, theofyllin, estere av aminosyrer, og N-methylglucamin. Både mono- og di-basiske salter kan fremstilles når kationet er énverdig. The free phosphonic acid compounds will form both organic and inorganic salts, and both are included in the invention. Examples of such salts are inorganic metal salts, such as the sodium, aluminium, potassium, ammonium, calcium, magnesium, silver and iron salts. Organic salts which may be mentioned as representative include the salts of primary, secondary or tertiary amines such as monoalkylamines, dialkylamines, trialkylamines and nitrogen-containing heterocyclic amines. Representative examples are salts with amines such as α-phenethylamine, diethylamine, diethylenetriamine, quinine, brucine, lysine, protamine, arginine, procaine, ethanolamine, morphine, benzylamine, ethylenediamine, N,N<*->dibenzylethylenediamine, diethanolamine, piperazine, N- aminoethylpiperazine, dimethylamino-ethanol, 2-amino-2-methyl-1-propanol, theophylline, esters of amino acids, and N-methylglucamine. Both mono- and di-basic salts can be prepared when the cation is monovalent.
Forbindelsene ifølge oppfinnelsen kan syntetiseres ved selektiv hydrogenering av en cis-propynylfosfonsyre, som vist strukturelt nedenfor: The compounds according to the invention can be synthesized by selective hydrogenation of a cis-propynylphosphonic acid, as shown structurally below:
Skjønt der er anvendt en syre ved illustrasjonen, kan fremgangsmåten like godt anvendes på salter. Although an acid is used in the illustration, the method can just as well be applied to salts.
Trinnet selektivt å redusere propynylsyren, saltet eller esteren for å danne propenylfosfonsyre eller det tilsvarende salt eller ester, utføres bekvemt ved å hydrogenere propynylforbind-elsen i nærvær av en passende hydrogeneringskatalysator som en edelmetall- eller Raney-nikkelkatalysator. Ved utførelse av hydrogeneringen for å få maksimale utbytter av den ønskede propen-ylf orbindelse , stanses hydrogeneringen når 1 mol hydrogen pr. mol utgangspropynylforbindelse er tatt opp for å hindre fullstendig metning av den umettede binding. Katalysatorer som er særlig nyttige ved denne reaksjon, er 5% palladium-på-calciumcarbonat eller Raney-nikkel. Disse katalysatorer inneholdende en liten mengde tilsatt gift for å nedsette deres aktivitet, kan også anvendes ved utførelse av den selektive hydrogenering. således kan det 5%-ige palladium-på-calciumcarbonat forgiftes ved tilsetning av en liten mengde blyacetat, og Raney-nikkel kan forgiftes ved tilsetning av en liten mengde zinkacetat og/eller en organisk base som piperidin, morfolin, kinolin og lignende. Disse forgiftede katalysatorer er særlig nyttige ved reduksjon av rene propynylfos-fonsyrer. Den spesielle katalysator og mengden som er nødvendig for hydrogeneringen vil avhenge delvis av renheten av propynylfor-bindelsen som reduseres, men i alminnelighet er en mengde katalysator mellom 1 og 5% tilstrekkelig for utførelse av denne selektive reduksjon. The step of selectively reducing the propynyl acid, salt or ester to form propenylphosphonic acid or the corresponding salt or ester is conveniently carried out by hydrogenating the propynyl compound in the presence of a suitable hydrogenation catalyst such as a noble metal or Raney nickel catalyst. When carrying out the hydrogenation to obtain maximum yields of the desired propene-yl bond, the hydrogenation is stopped when 1 mol of hydrogen per mol of starting propynyl compound is included to prevent complete saturation of the unsaturated bond. Catalysts that are particularly useful in this reaction are 5% palladium-on-calcium carbonate or Raney nickel. These catalysts containing a small amount of added poison to reduce their activity can also be used when carrying out the selective hydrogenation. thus the 5% palladium-on-calcium carbonate can be poisoned by adding a small amount of lead acetate, and Raney nickel can be poisoned by adding a small amount of zinc acetate and/or an organic base such as piperidine, morpholine, quinoline and the like. These poisoned catalysts are particularly useful in the reduction of pure propynylphosphonic acids. The particular catalyst and the amount required for the hydrogenation will depend in part on the purity of the propynyl compound being reduced, but generally an amount of catalyst between 1 and 5% is sufficient to effect this selective reduction.
Som oppløsningsmiddel anvendes bekvemt lavere alkanoler som methanol, ethanol eller isopropanol, skjønt oppløsningsmidlet er ikke kritisk. Positive hydrogentrykk på fra 1,4 til 7jO kg/cm overtrykk foretrekkes, men igjen kan høyere eller lavere trykk anvendes uten uheldig virkning. As a solvent, lower alkanols such as methanol, ethanol or isopropanol are conveniently used, although the solvent is not critical. Positive hydrogen pressures of from 1.4 to 7j0 kg/cm overpressure are preferred, but again higher or lower pressures can be used without adverse effect.
Representative eksempler på cis-propenylfosfonsyreforbind-elser fremstilt ved selektiv katalytisk hydrogenering av den tilsvarende propynylfosfonsyreforbindelse er alkali- og jordalkali-metallsalter som natrium-, kalium-, calcium- og magnesiumsalter og aminsalter eksempelvis benzylamin-, fenethylamin-, ammonium-, ethylendiamin-, piperazin- og kininsalter. Representative examples of cis-propenylphosphonic acid compounds produced by selective catalytic hydrogenation of the corresponding propynylphosphonic acid compound are alkali and alkaline earth metal salts such as sodium, potassium, calcium and magnesium salts and amine salts, for example benzylamine, phenethylamine, ammonium, ethylenediamine, piperazine and quinine salts.
cis-propanylfosfonsyre kan også fåes ved forsåpning av cis-propenylfosfonsyreestere. cis-propanylphosphonic acid can also be obtained by saponification of cis-propenylphosphonic acid esters.
De følgende eksempler er gitt for å illustrere oppfinnelsen. The following examples are given to illustrate the invention.
Eksempel 1 Example 1
10 g (0,043 mol) di-n-butylpropynylfosfonat ble oppløst i 10 g (0.043 mol) of di-n-butylpropynylphosphonate was dissolved in
50 ml methanol og hydrogenert i nærvær av 3 g 5%-ig palladium-på-calciumcarbonat forgiftet med blyacetat ved 2,8 kg/cm i et Parr-apparat. Efter opptagelse av 95% av den teoretiske mengde hydrogen ble reaksjonsblandingen filtrert for å fjerne katalysatoren, 50 ml of methanol and hydrogenated in the presence of 3 g of 5% palladium-on-calcium carbonate poisoned with lead acetate at 2.8 kg/cm in a Parr apparatus. After absorption of 95% of the theoretical amount of hydrogen, the reaction mixture was filtered to remove the catalyst,
og katalysatoren ble vasket med methanol. Filtratet ble konsentrert under nedsatt trykk, hvorved man fikk di-n-butyl-cis-propenylfosfonat i form av et blekt gult residuum. Residuet ble destillert and the catalyst was washed with methanol. The filtrate was concentrated under reduced pressure, whereby di-n-butyl-cis-propenylphosphonate was obtained in the form of a pale yellow residue. The residue was distilled
under nedsatt trykk, og 8,49 9 di-n-butyl-cis-propenylfosfonat som kokte' ved 72°C ved 0,12 mm, ble oppsamlet. Produktet hadde en under reduced pressure, and 8.49 g of di-n-butyl-cis-propenylphosphonate boiling at 72°C at 0.12 mm was collected. The product had one
analyse som svarte til C,,H_o0„P. Det infrarøde spektrum av produktet viste fravær av en acetylenbinding ved 4,5 \ i og nærvær av et olefinbånd ved 6,12 \ i, som er karakteristisk for cis-olef inet . NMR-spektret viste også at produktet var av cis-konfigurasjon. analysis which answered to C,,H_o0„P. The infrared spectrum of the product showed the absence of an acetylene bond at 4.5 µm and the presence of an olefinic band at 6.12 µm, which is characteristic of the cis-olefin. The NMR spectrum also showed that the product was of the cis configuration.
Di-n-butyl-propynylfosfonatet anvendt i dette eksempel ble fremstilt ved å tilsette en oppløsning av 0,5 mol methylacetylen-magnesiumbromid oppløst i en blanding av 2 liter benzen og 3O0 ml tetrahydrofuran dråpevis under omrøring til en oppløsning av 96,1 g (0,5 mol) di-n-butylklorfosfonat i 1 liter benzen. Methylacetylen-Grignard-reagenset ble tilsatt i løpet av 3 timer, og reaksjonsblandingen ble omrørt kraftig under tilsetningen mens temperaturen ble holdt under ca. 28°C. Efter at tilsetningen var avsluttet fikk den klare oppløsning lov til å stå ved værelsetemperatur i ca. 16 timer. 1 liter av en vandig ammoniumkloridoppløsning ble tilsatt til reaksjonsblandingen og vannskiktet ble fraskilt og ekstrahert to ganger med benzen. Benzenekstraktene ble forenet med benzenskiktet, og oppløsningsmidlet ble fordampet under nedsatt trykk, hvorved man fikk di-n-butylpropynylfosfonat i form av en olje som veiet 6l,5 g. Oljen ble destillert under nedsatt trykk og ga en tidlig fraksjon med kokepunkt på 111°C ved 0,5 mm og en klar gul flytende hovedfraksjon bestående av 47,3 g di-n-butylpropynylfosfonat som kokte ved 102°C ved 0,15 mm. The di-n-butyl-propynylphosphonate used in this example was prepared by adding a solution of 0.5 mol of methylacetylene-magnesium bromide dissolved in a mixture of 2 liters of benzene and 300 ml of tetrahydrofuran dropwise with stirring to a solution of 96.1 g ( 0.5 mol) of di-n-butyl chlorophosphonate in 1 liter of benzene. The methylacetylene-Grignard reagent was added over 3 hours, and the reaction mixture was vigorously stirred during the addition while the temperature was maintained below ca. 28°C. After the addition was finished, the clear solution was allowed to stand at room temperature for approx. 16 hours. 1 liter of an aqueous ammonium chloride solution was added to the reaction mixture and the aqueous layer was separated and extracted twice with benzene. The benzene extracts were combined with the benzene layer, and the solvent was evaporated under reduced pressure, whereby di-n-butylpropynylphosphonate was obtained in the form of an oil weighing 6l.5 g. The oil was distilled under reduced pressure and gave an early fraction with a boiling point of 111° C at 0.5 mm and a clear yellow liquid main fraction consisting of 47.3 g of di-n-butylpropynylphosphonate boiling at 102°C at 0.15 mm.
Da denne fremgangsmåte ble gjentatt under anvendelse av dimethyl-, di-t-butyl-, difenyl- eller di-p-tolyl-esteren av propynylfosfonsyre (erholdt fra det passende klorfosfonat og methylacethylen-Grignard-reagenset), fikk man den tilsvarende ester av cis-propenylfosfonsyre. When this procedure was repeated using the dimethyl, di-t-butyl, diphenyl, or di-p-tolyl ester of propynylphosphonic acid (obtained from the appropriate chlorophosphonate and methylacetylene Grignard reagent), the corresponding ester of cis-propenylphosphonic acid.
Eksempel 2 Example 2
Til en oppløsning av 9 g (0,044 mol) di-isopropylpropynyl-fosfonat i 50 ml methanol ble tilsatt 1,5 g 5%-ig palladium-på-calciumcarbonat forgiftet med blyacetat, og hydrogen ble ført gjennom oppløsningen ved 2,8 kg/cm . Efter opptagelse av 99,7% To a solution of 9 g (0.044 mol) of di-isopropylpropynyl phosphonate in 50 ml of methanol was added 1.5 g of 5% palladium-on-calcium carbonate poisoned with lead acetate, and hydrogen was passed through the solution at 2.8 kg/ cm. After admission of 99.7%
av den teoretiske mengde hydrogen, ble tilsetningen av hydrogen stanset, og reaksjonsblandingen ble filtrert fri for katalysator, og katalysatoren ble vasket med methanol. Konsentrasjon av filtratet under nedsatt trykk ga 8,84 g di-isopropyl-cis-propenylfosfonat. Dette materiale destillerte ved 42 - 43°C ved 0,15 mm. of the theoretical amount of hydrogen, the addition of hydrogen was stopped, and the reaction mixture was filtered free of catalyst, and the catalyst was washed with methanol. Concentration of the filtrate under reduced pressure gave 8.84 g of di-isopropyl-cis-propenylphosphonate. This material distilled at 42-43°C at 0.15 mm.
Di-ispropylpropynylfosfonatet anvendt i dette eksempel ble fremstilt i henhold til fremgangsmåten beskrevet i eksempel 1 ved å omsette di-isopropylklorfosfonat med methylacetylenmagnesium-bromid. Produktet ble erholdt i form av en olje med et kokepunkt på 82 - 84°C ved 0,4 - 0,45 mm. The di-isopropylpropynylphosphonate used in this example was prepared according to the method described in example 1 by reacting di-isopropyl chlorophosphonate with methylacetylene magnesium bromide. The product was obtained in the form of an oil with a boiling point of 82 - 84°C at 0.4 - 0.45 mm.
Eksempel 3 Example 3
9,7 g di-n-butyl-cis-propenylfosfonat ble kokt under til-bakeløp i 80 ml konsentrert (12,4 N) saltsyre i 15 timer i et olje-bad holdt ved 108 - H7°C. Reaksjonsblandingen fikk lov til å av-kjøle til værelsetemperatur hvorefter oppløsningen ble konsentrert i vakuum under oppvarmning. 50 ml vann ble tilsatt til residuet og inndampningsprosessen ble gjentatt, hvilket ga 6,19 g av et brunt viskøst residuum. Residuet ble oppløst i 25 ml ethylether, og etheroppløsningen ble ekstrahert med 3 x 10 ml vann. Inndampning av etherskiktet ga 2,56 g av et brunt residuum. Inndampning av de vandige ekstrakter i vakuum ga 3,43 g av en blek gul viskøs olje. Residuet erholdt fra vannekstraktet ble renset ved oppløs-ning i 25 ml ether, og ekstraksjon av etheroppløsningen med 12 ml vann. Inndampning av det vandige ekstrakt i vakuum under oppvarmning ga cis-propenylfosfonsyre, en blek gul viskøs olje. Infrarøde spektra av den gule olje viste det karakteristiske ole-finiske bånd ved 6,1 u. 9.7 g of di-n-butyl-cis-propenylphosphonate was refluxed in 80 ml of concentrated (12.4 N) hydrochloric acid for 15 hours in an oil bath maintained at 108-H7°C. The reaction mixture was allowed to cool to room temperature after which the solution was concentrated in vacuo under heating. 50 ml of water was added to the residue and the evaporation process was repeated, yielding 6.19 g of a brown viscous residue. The residue was dissolved in 25 ml of ethyl ether, and the ether solution was extracted with 3 x 10 ml of water. Evaporation of the ether layer gave 2.56 g of a brown residue. Evaporation of the aqueous extracts in vacuo gave 3.43 g of a pale yellow viscous oil. The residue obtained from the water extract was purified by dissolving in 25 ml of ether, and extracting the ether solution with 12 ml of water. Evaporation of the aqueous extract in vacuo with heating gave cis-propenylphosphonic acid, a pale yellow viscous oil. Infrared spectra of the yellow oil showed the characteristic olefinic band at 6.1 u.
Eksempel 4 Example 4
500 g (2,15 mol) di-n-butyl-propynylfosfonat oppløses i Dissolve 500 g (2.15 mol) of di-n-butyl-propynylphosphonate in
2,5 1 methanol i en hydrogeneringskolbe. Til dette tilsettes 50 g 5%-ig palladium-på-calciumcarbonat. Kolben ble fylt først med nitrogen og derpå med hydrogen ved alternativ evakuering og trykk-påføring. Hydrogentrykket ble brakt opp til 3,5 kg/cm overtrykk. Under 80 minutters rysting ble temperaturen hevet fra 25°C til 45°C, og 1,94 mol hydrogen ble absorbert. Ryst ingen ble stanset, reaktoren luftet og styrt med nitrogen. Katalysatoren ble fjernet ved filtrering, vasket med 200 ml methanol og methanolen fordampet i vakuum inntil temperaturen av residuet nådde 100°C. Residuet var di-n-butyl-cis-propenylfosfonat. 2.5 1 methanol in a hydrogenation flask. To this is added 50 g of 5% palladium-on-calcium carbonate. The flask was filled first with nitrogen and then with hydrogen by alternate evacuation and pressure application. The hydrogen pressure was brought up to 3.5 kg/cm overpressure. During 80 minutes of shaking, the temperature was raised from 25°C to 45°C, and 1.94 mol of hydrogen was absorbed. Shake no was stopped, the reactor vented and controlled with nitrogen. The catalyst was removed by filtration, washed with 200 ml of methanol and the methanol evaporated in vacuo until the temperature of the residue reached 100°C. The residue was di-n-butyl-cis-propenylphosphonate.
Eksempel 5 Example 5
Salter av cis-propenylfosfonsyre fremstilles ved behandling av den frie syre i ethanol med en base. Metallsaltene fåes ved å anvende et metalloxyd eller -hydroxyd som basen, og aminsaltene ved å anvende det passende amin. For å få et mono-salt innstilles pH med basen på 4,8 for metallsalter og 4,2 for aminsalter. For di-salter innstilles pH på 8,8 for metallsalter, 8,2 for aminsalter. For å utvinne saltet fjernes ethanolen ved fordampning i vakuum. Eksempelvis innstilles 2 g cis-propenylfosfonsyre i 50 ml ethanol på en pH av 4,8 med vandig natriumhydroxyd. Blandingen inndampes til tørrhet i vakuum for å få mono-natrium-cis-propenylfosfonat. Når vandig natriumhydroxyd tilsettes til ovenstående blanding til en pH på 8,8, og blandingen konsentreres til tørrhet, fåes di-natrium-cis-propenylfosfonat. Mono- og dibenzylaminsaltene fåes på samme måte ved å tilsette benzylamin til den ethanoliske opp-løsning av cis-propenylfosfonsyre til en pH på 4,2 eller 8,2. Hvilke som helst av de andre salter omtalt her, fåes på samme måte under anvendelse av den passende base. Salts of cis-propenylphosphonic acid are prepared by treating the free acid in ethanol with a base. The metal salts are obtained by using a metal oxide or hydroxide as the base, and the amine salts by using the appropriate amine. To obtain a mono-salt, the pH with the base is adjusted to 4.8 for metal salts and 4.2 for amine salts. For di-salts, the pH is set to 8.8 for metal salts, 8.2 for amine salts. To recover the salt, the ethanol is removed by evaporation in a vacuum. For example, 2 g of cis-propenylphosphonic acid in 50 ml of ethanol are adjusted to a pH of 4.8 with aqueous sodium hydroxide. The mixture is evaporated to dryness in vacuo to give mono-sodium cis-propenylphosphonate. When aqueous sodium hydroxide is added to the above mixture to a pH of 8.8, and the mixture is concentrated to dryness, disodium cis-propenylphosphonate is obtained. The mono- and dibenzylamine salts are obtained in the same way by adding benzylamine to the ethanolic solution of cis-propenylphosphonic acid to a pH of 4.2 or 8.2. Any of the other salts discussed herein are obtained in the same manner using the appropriate base.
Cis-propenylfosfonatesterne kan hydrolyseres til den frie syre som i eksempel 3, og overføres til et salt før epoxydering til (t) (cis-1,2-epoxypropyl)-fosfonater, alternativt kan propenyl-esterne epoxyderes og estergruppen så fjernes. Saltene epoxyderes direkte. Representative eksempler er de følgende og andre salter og estere epoxyderes på samme måte: 2,2 g (0,018 mol) cis-propenylfosfonsyre ble oppløst i 10 ml vann. pH av den vandige oppløsning ble innstilt på 5,6 - 6 ved tilsetning av 1,51 g, (0,017 mol) natriumbicarbonat for å danne nat rium-cis-propenylfosfonat. 0,55 g (0,0017 mol) natriumwolframat-dihydrat ble tilsatt, og den neste nøytrale oppløsning ble anbrakt på et vannbad og oppvarmet til 55°C. Vannbadet ble så fjernet, og 2 ml 30%-ig hydrogenperoxyd ble tilsatt til reaksjonsblandingen i løpet av IO minutter. Reaksjonen var eksoterm, og temperaturen steg til 65°C under tilsetningen av peroxydet. Ytterligere 1,6 mm hydrogenperoxyd ble tilsatt. Oxygen ble utviklet fra oppløsningen under tilsetningen, og temperaturen forble ved 55 - 57°C uten ytre oppvarmning. Efter henstand i 20 minutter falt temperaturen til 53°C. Reaksjonsblandingen ble så oppvarmet på vannbad ved 55°C i ytterligere 20 minutter, filtrert, og oppløsningen ble frysetørret, hvilket ga mono-natriumsaltet av (±) (cis-1,2-epoxypropyl)-fosfon- syre som et hvitt pulver som ble identifisert ved sitt NMR-spektrum. The cis-propenylphosphonate esters can be hydrolysed to the free acid as in example 3, and transferred to a salt before epoxidation to (t) (cis-1,2-epoxypropyl)-phosphonates, alternatively the propenyl esters can be epoxidized and the ester group then removed. The salts are epoxyd directly. Representative examples are the following and other salts and esters are epoxidized in the same way: 2.2 g (0.018 mol) of cis-propenylphosphonic acid was dissolved in 10 ml of water. The pH of the aqueous solution was adjusted to 5.6-6 by the addition of 1.51 g, (0.017 mol) sodium bicarbonate to form sodium cis-propenylphosphonate. 0.55 g (0.0017 mol) of sodium tungstate dihydrate was added, and the next neutral solution was placed on a water bath and heated to 55°C. The water bath was then removed and 2 ml of 30% hydrogen peroxide was added to the reaction mixture over 10 minutes. The reaction was exothermic, and the temperature rose to 65°C during the addition of the peroxide. An additional 1.6 mm of hydrogen peroxide was added. Oxygen was evolved from the solution during the addition, and the temperature remained at 55-57°C without external heating. After resting for 20 minutes, the temperature dropped to 53°C. The reaction mixture was then heated on a water bath at 55°C for an additional 20 minutes, filtered, and the solution lyophilized to give the monosodium salt of (±) (cis-1,2-epoxypropyl)-phosphono- acid as a white powder that was identified by its NMR spectrum.
Peroxytrifluoreddiksyre ble fremstilt ved fremgangsmåten ifølge Emmons (J. Am. Chem. Soc. 75, 4623 (1953). En oppløsning av 2,8 g peroxytrifluoreddiksyre i 20 ml kloroform ble så tilsatt til 5 g (0,022 mol) benzylammonium-cis-propenylfosfonat og 7 g fast dinatriumhydrogenfosfonat i 30 ml kloroform. Blandingen fikk lov til å stå i 16 timer ved 0°C. De faste stoffer ble så fraskilt ved filtrering. De faste stoffer ble suspendert i ca. 10 ml methanol, suspensjonen ble filtrert og methanolfiltratet inndampet til tørrhet i vakuum, hvilket ga et fast residuum av benzylammonium-(t)-(cis-1,2-epoxypropyl)-fosfonat. Produktet ble renset ved omkrystallisasjon fra 10 deler 95%-ig ethanol. Peroxytrifluoroacetic acid was prepared by the method of Emmons (J. Am. Chem. Soc. 75, 4623 (1953). A solution of 2.8 g of peroxytrifluoroacetic acid in 20 ml of chloroform was then added to 5 g (0.022 mol) of benzylammonium cis-propenylphosphonate and 7 g of solid disodium hydrogenphosphonate in 30 ml of chloroform. The mixture was allowed to stand for 16 hours at 0° C. The solids were then separated by filtration. The solids were suspended in about 10 ml of methanol, the suspension was filtered and the methanol filtrate evaporated to dryness in vacuo to give a solid residue of benzylammonium-(t)-(cis-1,2-epoxypropyl)phosphonate The product was purified by recrystallization from 10 parts of 95% ethanol.
I en 100 ml 3-halset rundkolbe forsynt med rører, termometer og tilsetningstrakt ble innført 6,4 9 (0,02 mol) dibenzyl-cis-propenylfosfonat og 30 ml kloroform. En oppløsning av 3»6 g 6.4 9 (0.02 mol) of dibenzyl-cis-propenylphosphonate and 30 ml of chloroform were introduced into a 100 ml 3-necked round flask equipped with a stirrer, thermometer and addition funnel. A solution of 3»6 g
(0,02 mol) mono-perfthalsyre i 20 ml ethylacetat ble tilsatt lang-somt og blandingen oppvarmet til 4o°C. Forløpet av reaksjonen ble fulgt ved gass-væskekromatografi av dibenzylesteren eller ved titrering av persyren. Reaksjonen var stort sett fullstendig efter 24 timer. på dette tidspunkt ble blandingen avkjølt til værelsetemperatur, fthalsyren fjernet ved filtrering og dibenzyl-(t)-(cis-1,2-epoxypropyl)-fosfonatet ble utvunnet ved å fjerne oppløsningsmidlet i vakuum. (0.02 mol) of mono-perphthalic acid in 20 ml of ethyl acetate was added slowly and the mixture heated to 40°C. The progress of the reaction was followed by gas-liquid chromatography of the dibenzyl ester or by titration of the peracid. The reaction was largely complete after 24 hours. at this point the mixture was cooled to room temperature, the phthalic acid was removed by filtration and the dibenzyl-(t)-(cis-1,2-epoxypropyl)phosphonate was recovered by removing the solvent in vacuo.
Claims (1)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67920367A | 1967-10-30 | 1967-10-30 | |
US72942068A | 1968-05-15 | 1968-05-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
NO133200B true NO133200B (en) | 1975-12-15 |
NO133200C NO133200C (en) | 1976-03-24 |
Family
ID=27102173
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO4276/68A NO133200C (en) | 1967-10-30 | 1968-10-29 |
Country Status (15)
Country | Link |
---|---|
AT (1) | AT292731B (en) |
BE (1) | BE723071A (en) |
CH (1) | CH531012A (en) |
DK (1) | DK132585C (en) |
ES (1) | ES359538A1 (en) |
FI (1) | FI51357C (en) |
FR (1) | FR1592151A (en) |
GB (1) | GB1239988A (en) |
IE (1) | IE32525B1 (en) |
IL (1) | IL30902A0 (en) |
LU (1) | LU57182A1 (en) |
MT (1) | MTP579B (en) |
NL (1) | NL6814978A (en) |
NO (1) | NO133200C (en) |
SE (1) | SE369910B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA774977B (en) * | 1976-09-06 | 1978-06-28 | Sab Soc Etudes Applic Biolog | Process for the preparation of 1,2-expoxypropyl-phosphonic acid derivatives |
EP2270021A1 (en) | 2009-06-18 | 2011-01-05 | Centre National de la Recherche Scientifique | Phosphonates synthons for the synthesis of phosphonates derivatives showing better bioavailability |
-
1968
- 1968-10-18 NL NL6814978A patent/NL6814978A/xx unknown
- 1968-10-20 IL IL30902A patent/IL30902A0/en unknown
- 1968-10-21 IE IE1257/68A patent/IE32525B1/en unknown
- 1968-10-21 CH CH1569868A patent/CH531012A/en not_active IP Right Cessation
- 1968-10-24 GB GB50636/68A patent/GB1239988A/en not_active Expired
- 1968-10-25 ES ES359538A patent/ES359538A1/en not_active Expired
- 1968-10-29 DK DK521968A patent/DK132585C/en active
- 1968-10-29 NO NO4276/68A patent/NO133200C/no unknown
- 1968-10-29 SE SE14617/68A patent/SE369910B/xx unknown
- 1968-10-29 FI FI683065A patent/FI51357C/en active
- 1968-10-29 BE BE723071D patent/BE723071A/xx unknown
- 1968-10-29 LU LU57182D patent/LU57182A1/xx unknown
- 1968-10-30 FR FR1592151D patent/FR1592151A/fr not_active Expired
- 1968-10-30 AT AT1055368A patent/AT292731B/en not_active IP Right Cessation
- 1968-10-30 MT MT579A patent/MTP579B/en unknown
Also Published As
Publication number | Publication date |
---|---|
GB1239988A (en) | 1971-07-21 |
IE32525B1 (en) | 1973-09-05 |
MTP579B (en) | 1969-10-13 |
ES359538A1 (en) | 1970-08-16 |
IE32525L (en) | 1969-04-30 |
DK132585C (en) | 1976-05-31 |
BE723071A (en) | 1969-04-29 |
LU57182A1 (en) | 1969-05-16 |
DK132585B (en) | 1976-01-05 |
NO133200C (en) | 1976-03-24 |
FI51357B (en) | 1976-08-31 |
DE1805677A1 (en) | 1969-12-11 |
CH531012A (en) | 1972-11-30 |
FI51357C (en) | 1976-12-10 |
AT292731B (en) | 1971-09-10 |
NL6814978A (en) | 1969-05-02 |
SE369910B (en) | 1974-09-23 |
FR1592151A (en) | 1970-05-11 |
IL30902A0 (en) | 1969-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2852573B1 (en) | N-[3-(2-carboxyethyl)phenyl]-piperidin-1-yl acetamide derivatives and their use as activators of soluble guanylate cyclase | |
DE1924085A1 (en) | Process for the decomposition of enantiomeric mixtures of (cis-1,2-epoxypropyl) -phosphonic acid derivatives | |
NO141090B (en) | N-PHOSPHONE MATHYLLYCINES FOR USE AS HERBICIDES AND / OR PHYTOTOXIC | |
IL24464A (en) | Benzimidazole compounds,their preparation,and physiologically active compositions containing them | |
JPS5823672A (en) | Manufacture of novel imidazolyl derivative and salt | |
DE1468341A1 (en) | Dibenzocycloheptane and heptene compounds and processes for their preparation | |
DD156369A5 (en) | PREPARATION OF RIGHT-TURNING 5-ARYL-2,3,4,4A, 5,9B-HEXAHYDRO-1H-PYRIDO [4,3B] -INDOLENES | |
CA1102329A (en) | Process for the preparation of new therapeutically useful isoquinoline and quinazoline derivatives | |
NO133200B (en) | ||
US2645594A (en) | Antiseptic acridane compounds | |
EP0371406B1 (en) | Oxyalkylated quaternary ammonium compounds, processes for production thereof, and plant growth regulating compositions containing said compounds | |
FR2694558A1 (en) | Disodium salt monohydrate of 4-chlorophenylthiomethylene bisphosphonic acid, its preparation, pharmaceutical compositions containing it. | |
EP0188502B1 (en) | Etherified 2-hydroxy-ethyl-phosphonic acid derivatives and plant growth regulating agents containing same as active ingredient | |
SU506296A3 (en) | Method for preparing 2-formyl-3-carbonamidoquinoxalin-di-oxides | |
US3929840A (en) | Labile esters of ({31 )(cis-1,2-epoxypropyl)phosphonic | |
US3849482A (en) | Amine salts of cis-propenylphosphonic acid | |
EP0112939A1 (en) | Derivatives of pentacyclo undecanes, processes for preparing these compounds, and pharmeceutical compositions thereof | |
SU1456017A3 (en) | Method of producing two-nucleous pyrazolidinones | |
WO1983002610A1 (en) | Derivatives of 3,3-dialkyl-indolin and of 3,3-alkylene-indolin, method for producing them and pharmaceutical preparations containing them | |
US3189429A (en) | Method of controlling plant growth | |
SU1450727A3 (en) | Method of regulating growth of crops | |
US2757196A (en) | L-3-(2-propynylthio) alanine | |
DE1005058B (en) | Process for the preparation of O, O-dialkylthiol or thiolthionophosphoric acid esters | |
SK2797A3 (en) | Pyrido£3,2,1-i,j|£3,1|benzoxazine derivatives, method of producing same and pharmaceutical composition containing these substances and their use in drugs | |
DE1924104A1 (en) | Alpha-hydroxy-beta-r-propyl-phosphonic acid esters - intermediates for epoxy-propyl phosphonic acid |